BioAtla reported a no-revenue QQ1 2026 quarter, with operating losses of $9.31 million and an EPS of -$4.22. The quarter marked a meaningful YoY improvement in operating performance as R&D and SG&A spend declined materially compared with QQ1 2025, underscoring the company’s ongoing focus on cost discipline during a period of active clinical development. Despite the narrowing loss, BioAtla remains cash-burn dependent and is positioned as a clinical-stage biotechnology company, where value realization hinges on upcoming trial data, regulatory milestones, and the ability to secure additional financing to fund pipeline advancement.
Key drivers for the quarter include a reduction in R&D and SG&A expenses (R&D: $4.58 million vs. $12.36 million in QQ1 2025; SG&A: $4.73 million vs. $5.26 million in QQ1 2025) which contributed to a 57.64% YoY improvement in operating income (from a larger loss to -$9.31 million) and a 47.16% sequential improvement QoQ. The company did not disclose revenue in QQ1 2026, consistent with its clinical-stage profile. Management commentary from the earnings call (not provided in the dataset) typically centers on pipeline progression (BA3011, BA3021, BA3071) and the need for strategic financing to sustain late-stage development.
Looking ahead, investors should monitor upcoming clinical milestones, potential partnership discussions, and the company’s ability to extend its cash runway through financings or collaborations. The investment thesis remains high-risk, high-reward, anchored to data readouts and the successful deployment of capital to advance a multi-candidate CAB ADC platform.
Key Performance Indicators
Operating Income
Increasing
-9.31M
QoQ: 47.16% | YoY: 57.64%
EPS
Decreasing
-4.22
QoQ: -1 523.08% | YoY: -859.09%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue: None reported in QQ1 2026. Gross Profit: None reported. Operating Income: -$9.308 million for QQ1 2026, versus a larger loss in QQ1 2025, representing a YoY improvement of 57.64% and a QoQ improvement of 47.16%. EBITDA: -$9.308 million. EPS (diluted): -$4.22 for QQ1 2026, with a YoY delta of -859.09% and a QoQ delta of -1,523.08%. Weighted Average Shares Outstanding (diluted): 1,501,649. R&D Expenses: $4.582 million. G&A Expenses: $4.726 million. Selling, General & Administrative Expenses: $4.726 million (consolidated). Total Operating Expenses: $9.308 million. Net Income: Not reported (null) for QQ1 2026, reflecting the pre-revenue clinical-stage nature. These figures reflect a substantial reduction in spending versus QQ1 2025, driven mainly by lower R&D and SG&A outlays as BioAtla conserves resources while advancing its pipeline.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-9.31M
57.64%
47.16%
EPS
-4.22
-859.09%
-1 523.08%
Key Financial Ratios
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.